High Gross MarginsA sustained gross margin near 67% indicates strong product-level economics typical for differentiated medical devices and consumables. This margin buffer supports long-term profitability as sales scale, enabling reinvestment in clinical studies, service infrastructure and product R&D without immediate margin pressure.

Very Low LeverageMinimal debt materially reduces financial risk and preserves flexibility to fund commercialization or trials via equity or partnership rather than interest-bearing obligations. Over a 2–6 month horizon this conservatism supports survivability during scaling and cushions against revenue volatility.

Recurring Revenue Model ElementsA business mix that includes consumables, service contracts and training creates recurring revenue potential tied to installed systems. As the installed base grows, these higher-margin, repeatable streams can stabilize cash flows and raise customer lifetime value, aiding durable commercialization.

Bears Say

Declining, Small Revenue BaseA shrinking and still small revenue base limits scale benefits and makes fixed costs burdensome, delaying operating leverage. Persisting revenue declines over several quarters hinder the firm's ability to fund trials, expand sales channels, and achieve self-sustaining growth without external financing.

Negative Operating And Free Cash FlowSustained negative operating and free cash flow forces reliance on external capital and increases dilution risk. Even with some improvement versus prior years, continued cash burn constrains investment in sales, clinical validation and regulatory work, slowing market penetration and long-term viability.

Eroding Equity And Heavy LossesOperating losses that materially erode equity reflect weak profitability and weaken the firm's financial resilience. Persistent steep net margins and declining equity limit capacity to invest organically, increase the likelihood of dilutive raises or restructuring, and impair long-term stakeholder confidence.

CLS.B FAQ

What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?

Clinical Laserthermia Systems AB Class B lowest stock price was kr2.43 and its highest was kr13.36 in the past 12 months.

What is Clinical Laserthermia Systems AB Class B’s market cap?

Clinical Laserthermia Systems AB Class B’s market cap is kr264.29M.

When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?

Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is May 15, 2026 which is in 82 days.

How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?

Currently, no data Available

Is Clinical Laserthermia Systems AB Class B overvalued?

According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Clinical Laserthermia Systems AB Class B pay dividends?

Clinical Laserthermia Systems AB Class B does not currently pay dividends.

What is Clinical Laserthermia Systems AB Class B’s EPS estimate?

Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Clinical Laserthermia Systems AB Class B have?

Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.

What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?

Currently, no hedge funds are holding shares in SE:CLS.B

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Clinical Laserthermia Systems AB Class B

Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.